Company research / HROW

Harrow, Inc. (HROW)

SEC name HARROW, INC. · CIK 0001360214 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Harrow, Inc. reported revenue of $272.30M. Revenue grew 36.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $275.59M.

Key ratios (year ended 2025-12-31)

75.1%
Gross margin
11.2%
Operating margin
-1.9%
Net margin
-9.8%
Return on year-end equity
36.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-05

Headquarters locality: Nashville · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$275.59M$272.30M$199.61M$130.19M$88.59M$72.48M$48.87M$51.16M$41.37M$26.77M$19.94M
Cost of Revenue$73.64M$67.93M$49.24M$39.64M$25.38M$18.21M$14.46M$16.75M$16.52M$13.51Mn/a
Gross Profit$201.96M$204.37M$150.37M$90.55M$63.21M$54.26M$34.41M$34.42M$24.85M$13.27M$10.11M
R&D Expense$29.01M$20.94M$12.23M$6.65M$3.05M$11.08M$2.41M$2.08M$825.0K$413.0K$739.0K
Operating Income-$2.75M$30.52M$8.82M$431.0K$1.92M$1.61M$385.0K-$4.79M-$5.22M-$12.16M-$15.88M
Depreciation & Amortization$1.87M$1.92M$1.85M$1.53M$1.48M$1.72M$1.88M$1.94M$1.61M$1.40M$1.05M
EBITDA-$880.0K$32.43M$10.67M$1.96M$3.40M$3.33M$2.27M-$2.86M-$3.61M-$10.76M-$14.83M
Net Income-$37.23M-$5.14M-$17.48M-$24.41M-$14.09M-$18.01M-$3.36M$168.0K$14.62M-$11.98M-$19.09M
EPS (Diluted)n/a-$0.14-$0.49-$0.75-$0.51n/a-$0.13$0.01$0.61-$0.60n/a
Total Assets$416.82M$399.48M$388.97M$312.16M$157.38M$98.33M$57.47M$59.09M$49.45M$23.92M$27.25M
Total Liabilities$401.97M$347.39M$319.67M$241.75M$130.14M$87.40M$30.65M$31.67M$24.70M$21.30M$20.82M
Long-Term Debtn/a$250.00M$262.74M$246.72M$151.77M$103.03M$20.00Mn/a$23.46M$23.46Mn/a
Shareholders' Equity$15.20M$52.45M$69.65M$70.77M$27.59M$11.29M$27.18M$27.71M$24.75M$2.62M$6.43M
Cash & Equivalents$83.89M$72.93M$47.25M$74.08M$96.27M$42.17M$4.10M$4.75Mn/a$4.02M$8.85M
Operating Cash Flow$6.25M$43.86M-$22.20M$3.84M$1.71M$5.08M-$1.10M$950.0K$687.0K-$8.80M-$11.21M
Capital Expenditures$1.24M$887.0K$1.59M$1.46M$2.60M$1.79M$862.0K$1.47M$1.77M$772.0K$6.89M
Free Cash Flow$5.02M$42.98M-$23.80M$2.38M-$892.0K$3.30M-$1.96M-$518.0K-$1.08M-$9.57M-$18.10M
Shares Outstanding37.48M37.23M35.62M35.17M29.90M26.90M25.75M25.53M24.34M20.62M18.63M
Weighted Average Diluted Sharesn/a36.76M35.65M32.62M27.46Mn/a25.90M26.47M23.81M20.03Mn/a
EPS (Basic)n/a-$0.14-$0.49-$0.75-$0.51-$0.69-$0.13$0.01$0.67-$0.60n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView